The hexosamine biosynthetic pathway and O-GlcNAcylation drive the expression of β-catenin and cell proliferation - PubMed (original) (raw)
. 2012 Feb 15;302(4):E417-24.
doi: 10.1152/ajpendo.00390.2011. Epub 2011 Nov 22.
Affiliations
- PMID: 22114026
- DOI: 10.1152/ajpendo.00390.2011
Free article
The hexosamine biosynthetic pathway and O-GlcNAcylation drive the expression of β-catenin and cell proliferation
Stéphanie Olivier-Van Stichelen et al. Am J Physiol Endocrinol Metab. 2012.
Free article
Abstract
The short half-life protooncogene β-catenin acquires a remarkable stability in a large subset of cancers, mainly from mutations affecting its proteasomal degradation. In this sense, colorectal cancers (CRC) form a group of pathologies in which early steps of development are characterized by an aberrant expression of β-catenin and an uncontrolled proliferation of epithelial cells. Diet has long been described as an influence in the emergence of CRC, but the molecular events that link metabolic disorders and CRC remain elusive. Part of the explanation may reside in hexosamine biosynthetic pathway (HBP) flux. We found that fasted mice being force-fed with glucose or glucosamine leads to an increase of β-catenin and O-GlcNAcylation levels in the colon. MCF7 cells possessing intact Wnt/β-catenin signaling heavily expressed β-catenin when cultured in high glucose; this was reversed by the HBP inhibitor azaserine. HBP inhibition also decreased the expression of β-catenin in HT29 and, to a lesser extent, HCT116 cells. The same observation was made with regard to the transcriptional activity of β-catenin in HEK293 cells. Inhibition of HBP also blocked the glucose-mediated proliferation capacity of MCF7 cells, demonstrating that glucose affects both β-catenin expression and cell proliferation through the HBP. The ultimate element conducting these events is the dynamic posttranslational modification O-GlcNAcylation, which is intimately linked to HBP; the modulation of its level affected the expression of β-catenin and cell proliferation. In accordance with our findings, we propose that metabolic disorders correlate to CRC via an upregulation of HBP that reverberates on high O-GlcNAcylation levels including modification of β-catenin.
Similar articles
- Elevated glucose levels impair the WNT/β-catenin pathway via the activation of the hexosamine biosynthesis pathway in endometrial cancer.
Zhou F, Huo J, Liu Y, Liu H, Liu G, Chen Y, Chen B. Zhou F, et al. J Steroid Biochem Mol Biol. 2016 May;159:19-25. doi: 10.1016/j.jsbmb.2016.02.015. Epub 2016 Feb 26. J Steroid Biochem Mol Biol. 2016. PMID: 26923859 - Preclinical evaluation of destruxin B as a novel Wnt signaling target suppressing proliferation and metastasis of colorectal cancer using non-invasive bioluminescence imaging.
Yeh CT, Rao YK, Ye M, Wu WS, Chang TC, Wang LS, Wu CH, Wu AT, Tzeng YM. Yeh CT, et al. Toxicol Appl Pharmacol. 2012 May 15;261(1):31-41. doi: 10.1016/j.taap.2012.03.007. Epub 2012 Mar 23. Toxicol Appl Pharmacol. 2012. PMID: 22465936 - O-GlcNAcylation stabilizes β-catenin through direct competition with phosphorylation at threonine 41.
Olivier-Van Stichelen S, Dehennaut V, Buzy A, Zachayus JL, Guinez C, Mir AM, El Yazidi-Belkoura I, Copin MC, Boureme D, Loyaux D, Ferrara P, Lefebvre T. Olivier-Van Stichelen S, et al. FASEB J. 2014 Aug;28(8):3325-38. doi: 10.1096/fj.13-243535. Epub 2014 Apr 17. FASEB J. 2014. PMID: 24744147 Free PMC article. - The hexosamine biosynthetic pathway and cancer: Current knowledge and future therapeutic strategies.
Lam C, Low JY, Tran PT, Wang H. Lam C, et al. Cancer Lett. 2021 Apr 10;503:11-18. doi: 10.1016/j.canlet.2021.01.010. Epub 2021 Jan 20. Cancer Lett. 2021. PMID: 33484754 Review. - Targeting Protein _O_-GlcNAcylation, a Link between Type 2 Diabetes Mellitus and Inflammatory Disease.
Bolanle IO, Palmer TM. Bolanle IO, et al. Cells. 2022 Feb 17;11(4):705. doi: 10.3390/cells11040705. Cells. 2022. PMID: 35203353 Free PMC article. Review.
Cited by
- O-GlcNAcylation-inducing treatments inhibit estrogen receptor α expression and confer resistance to 4-OH-tamoxifen in human breast cancer-derived MCF-7 cells.
Kanwal S, Fardini Y, Pagesy P, N'tumba-Byn T, Pierre-Eugène C, Masson E, Hampe C, Issad T. Kanwal S, et al. PLoS One. 2013 Jul 11;8(7):e69150. doi: 10.1371/journal.pone.0069150. Print 2013. PLoS One. 2013. PMID: 23935944 Free PMC article. - Targeting cancer's metabolic co-dependencies: A landscape shaped by genotype and tissue context.
Bi J, Wu S, Zhang W, Mischel PS. Bi J, et al. Biochim Biophys Acta Rev Cancer. 2018 Aug;1870(1):76-87. doi: 10.1016/j.bbcan.2018.05.002. Epub 2018 May 23. Biochim Biophys Acta Rev Cancer. 2018. PMID: 29775654 Free PMC article. Review. - GFAT1/HBP/O-GlcNAcylation Axis Regulates _β_-Catenin Activity to Promote Pancreatic Cancer Aggressiveness.
Jia C, Li H, Fu D, Lan Y. Jia C, et al. Biomed Res Int. 2020 Feb 15;2020:1921609. doi: 10.1155/2020/1921609. eCollection 2020. Biomed Res Int. 2020. PMID: 32149084 Free PMC article. - Cross regulation between mTOR signaling and O-GlcNAcylation.
Very N, Steenackers A, Dubuquoy C, Vermuse J, Dubuquoy L, Lefebvre T, El Yazidi-Belkoura I. Very N, et al. J Bioenerg Biomembr. 2018 Jun;50(3):213-222. doi: 10.1007/s10863-018-9747-y. Epub 2018 Mar 9. J Bioenerg Biomembr. 2018. PMID: 29524020 - The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer.
Kim J, Lee HM, Cai F, Ko B, Yang C, Lieu EL, Muhammad N, Rhyne S, Li K, Haloul M, Gu W, Faubert B, Kaushik AK, Cai L, Kasiri S, Marriam U, Nham K, Girard L, Wang H, Sun X, Kim J, Minna JD, Unsal-Kacmaz K, DeBerardinis RJ. Kim J, et al. Nat Metab. 2020 Dec;2(12):1401-1412. doi: 10.1038/s42255-020-00316-0. Epub 2020 Nov 30. Nat Metab. 2020. PMID: 33257855 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous